Short answer
Eton Pharmaceuticals, Inc. (ETON) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Danka Radosavljevic appointed Chief Operating Officer effective July 31, 2026.
Eton Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Danka Radosavljevic appointed Chief Operating Officer effective July 31, 2026
- Promotion of five-year operations leader preserves continuity across quality, regulatory, supply chain and product development
- Annual base salary set at $520,800
- Target discretionary incentive bonus equals 50% of base salary, tied to corporate and individual performance targets
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Eton Pharmaceuticals, Inc. 8-K filings
Get the next ETON 8-K as it lands
Follow ETON for push alerts, or ask the research agent what this filing means.